» Articles » PMID: 35164140

A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease Between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Feb 15
PMID 35164140
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) embraces several forms of liver disorders involving fat disposition in hepatocytes ranging from simple steatosis to the severe stage, namely, non-alcoholic steatohepatitis (NASH). Recently, several experimental in vivo animal models for NAFLD/NASH have been established. However, no reproducible experimental animal model displays the full spectrum of pathophysiological, histological, molecular, and clinical features associated with human NAFLD/NASH progression. Although methionine-choline-deficient (MCD) diet and high-fat diet (HFD) models can mimic histological and metabolic abnormalities of human disease, respectively, the molecular signaling pathways are extremely important for understanding the pathogenesis of the disease. This review aimed to assess the differences in gene expression patterns and NAFLD/NASH progression pathways among the most common dietary animal models, i.e., HFD- and MCD diet-fed animals. Studies showed that the HFD and MCD diet could induce either up- or downregulation of the expression of genes and proteins that are involved in lipid metabolism, inflammation, oxidative stress, and fibrogenesis pathways. Interestingly, the MCD diet model could spontaneously develop liver fibrosis within two to four weeks and has significant effects on the expression of genes that encode proteins and enzymes involved in the liver fibrogenesis pathway. However, such effects in the HFD model were found to occur after 24 weeks with insulin resistance but appear to cause less severe fibrosis. In conclusion, assessing the abnormal gene expression patterns caused by different diet types provides valuable information regarding the molecular mechanisms of NAFLD/NASH and predicts the clinical progression of the disease. However, expression profiling studies concerning genetic variants involved in the development and progression of NAFLD/NASH should be conducted.

Citing Articles

Microbiota-derived HS induces c-kit cDC1 autophagic cell death and liver inflammation in metabolic dysfunction-associated steatohepatitis.

Song Y, Li N, Jiang S, Wang K, Lv G, Fan Z Nat Commun. 2025; 16(1):2222.

PMID: 40044736 PMC: 11882788. DOI: 10.1038/s41467-025-57574-3.


Protocatechuic Acid Protects Mice Against Non-Alcoholic Fatty Liver Disease by Attenuating Oxidative Stress and Improving Lipid Profile.

Zeinalian Boroujeni Z, Khorsandi L, Zeidooni L, Badiee M, Khodayar M Rep Biochem Mol Biol. 2025; 13(2):218-230.

PMID: 39995650 PMC: 11847584. DOI: 10.61186/rbmb.13.2.218.


In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration.

Hu Y, Zhang Z, Adiham A, Li H, Gu J, Gong P Int J Mol Sci. 2025; 26(2).

PMID: 39859410 PMC: 11766297. DOI: 10.3390/ijms26020696.


L. Leaf Extract Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the AMPK Pathway in High Fat-Fed C57BL/6 Mice.

Gu M, Ahn Y, Lee Y, Yoo G, Kim Y, Choi I Nutrients. 2024; 16(23).

PMID: 39683561 PMC: 11644762. DOI: 10.3390/nu16234165.


LncRNA aggravates hepatic steatosis via PPARγ signaling.

Xie X, Gao M, Zhao W, Li C, Zhang W, Yang J Elife. 2024; 13.

PMID: 39436790 PMC: 11495842. DOI: 10.7554/eLife.96988.


References
1.
Tipoe G, Ho C, Liong E, Leung T, Lau T, Fung M . Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD). Histol Histopathol. 2009; 24(9):1161-9. DOI: 10.14670/HH-24.1161. View

2.
Larter C, Yeh M, Williams J, Bell-Anderson K, Farrell G . MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol. 2008; 49(3):407-16. DOI: 10.1016/j.jhep.2008.03.026. View

3.
Oz H, Chen T, Neuman M . Methionine deficiency and hepatic injury in a dietary steatohepatitis model. Dig Dis Sci. 2007; 53(3):767-76. PMC: 2271115. DOI: 10.1007/s10620-007-9900-7. View

4.
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K . Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol. 2006; 536(1-2):182-91. DOI: 10.1016/j.ejphar.2006.02.028. View

5.
Larter C, Yeh M . Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008; 23(11):1635-48. DOI: 10.1111/j.1440-1746.2008.05543.x. View